Canada Markets open in 1 hr 38 mins

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2530-0.0001 (-0.04%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.2531
Open0.2750
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2380 - 0.2800
52 Week Range0.2150 - 0.6000
Volume1,173,798
Avg. Volume770,974
Market Cap80.57M
Beta (5Y Monthly)0.10
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateFeb. 28, 2022 - Mar. 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

    701 subjects dosed to dateInitiating enrollment activities in Turkey as part of its clinical diversification plans to support global regulatory approvals On-track to complete enrollment in Q1-2022 and FDA submission thereafterCommencing regulatory package activities for submission to international regulatory authorities for drug approvals TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sci

  • GlobeNewswire

    Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

    IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psilocybin pharmaceutical de

  • GlobeNewswire

    Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

    Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, wishes to clarify certain disclosures in its press release titl